24027-80-3 Usage
Description
2',3'-Dideoxyadenosine triphosphoric acid (DDATP) is a modified nucleotide adenosine that is utilized in research and diagnostic applications. It closely resembles adenosine triphosphate (ATP), which is the primary energy source for cellular processes. However, DDATP has two oxygen atoms removed from the ribose sugar moiety at the 2' and 3' positions. This alteration prevents the formation of a phosphodiester linkage, which effectively halts DNA synthesis when DDATP is integrated into a growing DNA strand by DNA polymerase.
Uses
Used in Nucleic Acid Sequencing:
2',3'-Dideoxyadenosine triphosphoric acid (DDATP) is used as a termination agent in nucleic acid sequencing for determining the order of nucleotides in DNA and RNA molecules. Its incorporation into a growing DNA strand by DNA polymerase leads to the termination of DNA synthesis, allowing for the identification of the nucleotide sequence.
Used in Molecular Biology Techniques:
In molecular biology, 2',3'-Dideoxyadenosine triphosphoric acid (DDATP) is used as a research tool to study the structure and function of DNA and RNA. Its unique properties enable the investigation of various biological processes and mechanisms.
Used in Antiviral Drug Development:
2',3'-Dideoxyadenosine triphosphoric acid (DDATP) is used as a potential antiviral agent for inhibiting viral DNA synthesis. Its ability to terminate DNA synthesis can be harnessed to develop new antiviral therapies that target viral replication processes.
Check Digit Verification of cas no
The CAS Registry Mumber 24027-80-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,4,0,2 and 7 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 24027-80:
(7*2)+(6*4)+(5*0)+(4*2)+(3*7)+(2*8)+(1*0)=83
83 % 10 = 3
So 24027-80-3 is a valid CAS Registry Number.
24027-80-3Relevant articles and documents
Anti-retroviral agents and delivery systems for the same
-
, (2008/06/13)
The present invention provides a method for preventing or treating disease caused by retroviruses, particularly human immunodeficiency virus. Liposomes are prepared containing phosphorylated derivatives of nucle-osides which act as chain-terminators of viral DNA. The phosphorylated nucleosides perse, without encapsulation in liposomes, do not readily enter cells. However, they are found to be effective if encapsulated in liposomes because they remain in liposomes longer, they do not escape easily from cells, and they constitute the active form for incorporation in viral DNA chains. When administered to a host, the liposomes are taken up by endocytic and phagocytic cells, which are important reservoirs of HIV infection. If coated with an appro-priate ligand, such as an immunoglobulin molecule, lipo-somes containing the phosphorylated nucleosides can be directed to phagocytic cells, CD4-positive cells, or infected host cells.
